Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Ending Cash Position : ¥787 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co Ending Cash Position?

Nanjing King-Friend Biochemical Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥787 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 (¥545 Mil) to Dec. 2023 (¥894 Mil) but then declined from Dec. 2023 (¥894 Mil) to Mar. 2024 (¥787 Mil).

Nanjing King-Friend Biochemical Pharmaceutical Co's annual Ending Cash Position declined from Dec. 2021 (¥435 Mil) to Dec. 2022 (¥303 Mil) but then increased from Dec. 2022 (¥303 Mil) to Dec. 2023 (¥894 Mil).

Nanjing King-Friend Biochemical Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co Ending Cash Position Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

248.44

473.22

434.65

302.68

894.19

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															654.86	609.89	544.90	894.19	786.78

Nanjing King-Friend Biochemical Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nanjing King-Friend Biochemical Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	302.674	+	591.511
	=	894

Nanjing King-Friend Biochemical Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	894.185	+	-107.407
	=	787

Nanjing King-Friend Biochemical Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061

Website

http://www.nkf-pharma.com

Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.

Executives

Huang Xi Wei	Director
Liu Zu Qing	Supervisors
Xie Ju Hua	Director
Wu Gui Ping	senior management
Tang Yong Qun	Director
Qian Xiao Jie	senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines